These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34405140)

  • 1. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE).
    Pérez-Martínez A; Mora-Rillo M; Ferreras C; Guerra-García P; Pascual-Miguel B; Mestre-Durán C; Borobia AM; Carcas AJ; Queiruga-Parada J; García I; Sánchez-Zapardiel E; Gasior M; De Paz R; Marcos A; Vicario JL; Balas A; Moreno MA; Eguizabal C; Solano C; Arribas JR; Buckley RM; Montejano R; Soria B
    EClinicalMedicine; 2021 Sep; 39():101086. PubMed ID: 34405140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210).
    Ferreras C; Hernández-Blanco C; Martín-Quirós A; Al-Akioui-Sanz K; Mora-Rillo M; Ibáñez F; Díaz-Almirón M; Cano-Ochando J; Lozano-Ojalvo D; Jiménez-González M; Goterris R; Sánchez-Zapardiel E; de Paz R; Guerra-García P; Queiruga-Parada J; Molina P; Briones ML; Ruz-Caracuel B; Borobia AM; Carcas AJ; Planelles D; Vicario JL; Moreno MÁ; Balas A; Llano M; Llorente A; Del Balzo Á; Cañada C; García MÁ; Calvin ME; Arenas I; Pérez de Diego R; Eguizábal C; Soria B; Solano C; Pérez-Martínez A
    Cytotherapy; 2024 Jan; 26(1):25-35. PubMed ID: 37897472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol.
    García-García I; Guerra-García P; Ferreras C; Borobia AM; Carcas AJ; Queiruga-Parada J; Vicario JL; Mirones I; Solano C; Eguizabal C; Soria B; Pérez-Martínez A
    Trials; 2021 Oct; 22(1):674. PubMed ID: 34600562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy.
    Ferreras C; Pascual-Miguel B; Mestre-Durán C; Navarro-Zapata A; Clares-Villa L; Martín-Cortázar C; De Paz R; Marcos A; Vicario JL; Balas A; García-Sánchez F; Eguizabal C; Solano C; Mora-Rillo M; Soria B; Pérez-Martínez A
    Front Cell Dev Biol; 2021; 9():620730. PubMed ID: 33718360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
    Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
    Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
    Daveson AJM; Ee HC; Andrews JM; King T; Goldstein KE; Dzuris JL; MacDougall JA; Williams LJ; Treohan A; Cooreman MP; Anderson RP
    EBioMedicine; 2017 Dec; 26():78-90. PubMed ID: 29191561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines.
    Bravo-Grande JL; Asunción Blanco-González M; de la Torre-Robles JM; Asmat-Inostrosa MP; Fernández-Escribano M; Villalobos IM; Covadonga Caso-Pita M; Hervella-Ordoñez M; Cañibano Cimas LM; de la Fuente-Martín JM; Luisa Rodríguez de la Pinta M; Olivas JRB; Muñóz-Ruipérez C; Alonso López MA; Del Campo MT; Antonieta Ramírez Pérez M; Sánchez-Arcilla I; Marzola-Payares M; Rescalvo-Santiago F; Paula-Ortiz M; Sánchez-Santos JM; López-Pérez R
    Vaccine; 2021 Jan; 39(3):554-563. PubMed ID: 33334613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
    Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
    Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
    Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
    Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccinated and Convalescent Donor-Derived Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells as Adoptive Immunotherapy for High-Risk Coronavirus Disease 2019 Patients.
    Papayanni PG; Chasiotis D; Koukoulias K; Georgakopoulou A; Iatrou A; Gavriilaki E; Giannaki C; Bitzani M; Geka E; Tasioudis P; Chloros D; Fylaktou A; Kioumis I; Triantafyllidou M; Dimou-Besikli S; Karavalakis G; Boutou AK; Siotou E; Anagnostopoulos A; Papadopoulou A; Yannaki E
    Clin Infect Dis; 2021 Dec; 73(11):2073-2082. PubMed ID: 33905481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
    Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
    Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
    Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
    Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.